Results 11 to 20 of about 5,633 (170)

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing. [PDF]

Clin Pharmacol Ther
Post‐kala‐azar dermal leishmaniasis (PKDL) involves a high macrophage burden in which the Leishmania parasites reside. Liposomal amphotericin B (LAmB) plays a key role in the treatment of PKDL. The mononuclear phagocyte system (MPS) is crucial in the distribution of liposomal drugs as well as the leishmaniasis pathophysiology.
Chu WY, Singh OP, Sundar S, Mondal D, Pandey K, Das P, Roseboom IC, Raja S, Torres A, Carrillo E, Huitema ADR, Alves F, Dorlo TPC.   +12 more
europepmc   +2 more sources

Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis

Journal of Immunology Research, 2020
Cutaneous leishmaniasis (CL) due to L. braziliensis is associated with an exaggerated inflammatory response and tissue damage. Miltefosine is more effective than pentavalent antimony (Sbv) in the treatment of CL, and here, we evaluate the ability of Sbv,
Fábio Peixoto, Maurício T. Nascimento, Rúbia Costa, Juliana Silva, Gaby Renard, Luiz Henrique Guimarães, Gerson Penna, Manoel Barral-Netto, Lucas P. Carvalho, Paulo R. L. Machado, Edgar M. Carvalho   +10 more
doaj   +1 more source

Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis

Journal of Infection in Developing Countries, 2019
Introduction: Although miltefosine is the first line for treatment of leishmaniasis, it could have multiple un-recognized effects if any infection accidentally takes place during therapy.
Ashraf M Barakat, Amal E Saafan, Samuel T Melek, Tahany S Behour, Nehal M Khairy, Ahmed S Khairalla   +5 more
doaj   +1 more source

Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. [PDF]

PLoS Neglected Tropical Diseases, 2017
BACKGROUND:Since miltefosine monotherapy against visceral leishmaniasis (VL) caused by Leishmania donovani has been discontinued in the Indian subcontinent due to an increase in the number of treatment failures, single dose liposomal amphotericin B is ...
Sarah Hendrickx, Magali Van den Kerkhof, Dorien Mabille, Paul Cos, Peter Delputte, Louis Maes, Guy Caljon   +6 more
doaj   +1 more source

Induction of Apoptosis by Miltefosine in Iranian Strain of Leishmania infantum Promastigotes [PDF]

Iranian Journal of Parasitology, 2009
Background: Miltefosine is a new drug of choice for the treatment of visceral leishmaniasis. Numerous experi­mental studies have shown miltefosine is effective on Leishmania donovani, however, effectiveness of miltefos­ine in treatment of L.
S Khademvatan, MJ Gharavi, L Akhlaghi, A Samadikuchaksaraei, K Mousavizadeh, R Hadighi, J Saki   +6 more
doaj   +1 more source

The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil

Memorias do Instituto Oswaldo Cruz, 2011
The in vitro leishmanicidal activity of miltefosine® (Zentaris GmbH) was assessed against four medically relevant Leishmania species of Brazil: Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, Leishmania (Viannia) guyanensis and ...
Eliane de Morais-Teixeira, Quesia Souza Damasceno, Mariana Kolos Galuppo, Alvaro José Romanha, Ana Rabello   +4 more
doaj   +1 more source

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol

Parasites & Vectors, 2021
Background Leishmania infantum is the most important etiological agent of visceral leishmaniasis in the Americas and Mediterranean region, and the dog is the main host.
Gustavo Gonçalves, Monique Paiva Campos, Alessandra Silva Gonçalves, Lia Carolina Soares Medeiros, Fabiano Borges Figueiredo   +4 more
doaj   +1 more source

Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. [PDF]

PLoS Neglected Tropical Diseases, 2015
BACKGROUND:Recent studies have shown significant decline in the final cure rate after miltefosine treatment in visceral leishmaniasis. This study evaluates the efficacy of miltefosine in the treatment of post kala-azar dermal leishmaniasis (PKDL ...
V Ramesh, Ruchi Singh, Kumar Avishek, Aditya Verma, Deepak Kumar Deep, Sandeep Verma, Poonam Salotra   +6 more
doaj   +1 more source

Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis

Pharmaceutics, 2022
This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device that would allow sustained and localized miltefosine release for the treatment of Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine doses by solvent-
Lin Chen, Liangju Kuang, Amy E. Ross, Wissam Farhat, Nikolay Boychev, Sina Sharfi, Levi N. Kanu, Longqian Liu, Daniel S. Kohane, Joseph B. Ciolino   +9 more
doaj   +1 more source

Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era

Microbiology Spectrum
Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of Leishmania donovani parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing
Sushmita Ghosh, Aditya Verma, Dhiraj Kumar, Deepak Kumar Deep, V. Ramesh, Poonam Salotra, Ruchi Singh   +6 more
doaj   +1 more source